Gyre Therapeutics, Inc.
GYRE
$8.11
$0.354.51%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -87.47% | -64.18% | 99.90% | -71.73% | 90.39% |
| Total Depreciation and Amortization | 181.14% | 28.92% | 52.92% | 124.75% | -28.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 41.18% | 14.23% | -99.27% | -54.15% | -38.48% |
| Change in Net Operating Assets | 95.38% | 20.14% | -135.56% | -173.71% | -1,667.43% |
| Cash from Operations | 138.01% | -104.47% | -182.08% | -77.24% | -221.18% |
| Capital Expenditure | 82.42% | 47.19% | 102.80% | 64.89% | 41.22% |
| Sale of Property, Plant, and Equipment | -91.74% | -98.00% | -17.37% | -101.38% | 62.69% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 60.14% | 129.66% | -57.53% | 55.42% | -23.25% |
| Cash from Investing | 63.23% | 127.24% | -249.66% | 55.80% | -2.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 8,638.91% | 122.64% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,312.61% | -- | -- | -- | -- |
| Cash from Financing | 14,227.56% | 104.26% | -61.44% | -- | -- |
| Foreign Exchange rate Adjustments | 162.82% | 208.70% | -210.39% | -38.01% | 91.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 256.68% | 186.79% | -154.55% | -109.82% | -209.82% |